Xiaoling Ding1, Jie Zhang2, Ziqin Feng3, Qianru Tang3, Xiaorong Zhou4. 1. Department of Gastroenterology, The Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, Jiangsu, 226001, China. 2. Department of Immunology, School of Medicine, Nantong University, 19 Qixiu Road, Nantong, 226019, Jiangsu, China. 3. School of Medicine, Nantong University, Nantong, 226019, Jiangsu, China. 4. Department of Immunology, School of Medicine, Nantong University, 19 Qixiu Road, Nantong, 226019, Jiangsu, China. zhouxiaorong@ntu.edu.cn.
Abstract
BACKGROUND: In colorectal cancer (CRC), miR-137-3p downregulation is associated with disease progression, but the mechanism is not fully understood. KDM1A, also known as LSD1, is upregulated in various cancer and promotes tumor metastasis. Interestingly, miR-137-3p is downregulated by hypoxia, which plays critical roles in tumor metastasis, and KDM1A is a miR-137-3p target gene in brain tumors. AIMS: To study if CRC metastasis is regulated by a hypoxia/miR-137-3p/KDM1A axis and if the epithelial-mesenchymal transition (EMT) process is involved. METHODS: We measured the levels of miR-137-3p, KDM1A, and some EMT markers in CRC biopsy tissues and cell lines. We also investigated the regulation of KDM1A by miR-137-3p and the effects of KDM1A inhibition on the EMT process and cell migration. RESULTS: We verified the low miR-137-3p and high KDM1A levels in CRC tumors. Inhibiting miR-137-3p upregulated KDM1A expression and promoted the invasiveness of CRC cells. KDM1A knockdown, or treatment with tranylcypromine, a specific KDM1A inhibitor, reduced the migration and invasion of CRC cells by inhibiting the EMT process. CRC cells cultured under hypoxic conditions expressed less miR-137-3p but more KDM1A than cells cultured under normal conditions, implying the involvement of miR-137-3p and KDM1A in hypoxia-induced tumor metastasis. CONCLUSIONS: We conclude that MiR-137-3p inhibits CRC cell migration by regulating a KDM1A-dependent EMT process. Our study suggests that restoring the expression of miR-137-3p or targeting KDM1A might be potential therapeutic strategies for CRC.
BACKGROUND: In colorectal cancer (CRC), miR-137-3p downregulation is associated with disease progression, but the mechanism is not fully understood. KDM1A, also known as LSD1, is upregulated in various cancer and promotes tumor metastasis. Interestingly, miR-137-3p is downregulated by hypoxia, which plays critical roles in tumor metastasis, and KDM1A is a miR-137-3p target gene in brain tumors. AIMS: To study if CRC metastasis is regulated by a hypoxia/miR-137-3p/KDM1A axis and if the epithelial-mesenchymal transition (EMT) process is involved. METHODS: We measured the levels of miR-137-3p, KDM1A, and some EMT markers in CRC biopsy tissues and cell lines. We also investigated the regulation of KDM1A by miR-137-3p and the effects of KDM1A inhibition on the EMT process and cell migration. RESULTS: We verified the low miR-137-3p and high KDM1A levels in CRC tumors. Inhibiting miR-137-3p upregulated KDM1A expression and promoted the invasiveness of CRC cells. KDM1A knockdown, or treatment with tranylcypromine, a specific KDM1A inhibitor, reduced the migration and invasion of CRC cells by inhibiting the EMT process. CRC cells cultured under hypoxic conditions expressed less miR-137-3p but more KDM1A than cells cultured under normal conditions, implying the involvement of miR-137-3p and KDM1A in hypoxia-induced tumor metastasis. CONCLUSIONS: We conclude that MiR-137-3p inhibits CRC cell migration by regulating a KDM1A-dependent EMT process. Our study suggests that restoring the expression of miR-137-3p or targeting KDM1A might be potential therapeutic strategies for CRC.
Authors: Shinya Hayami; John D Kelly; Hyun-Soo Cho; Masanori Yoshimatsu; Motoko Unoki; Tatsuhiko Tsunoda; Helen I Field; David E Neal; Hiroki Yamaue; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto Journal: Int J Cancer Date: 2011-02-01 Impact factor: 7.396
Authors: Marcin Włodarczyk; Jakub Włodarczyk; Paweł Siwiński; Aleksandra Sobolewska-Włodarczyk; Jakub Fichna Journal: Curr Drug Targets Date: 2018 Impact factor: 3.465
Authors: Satoi Nagasawa; Anna S Sedukhina; Yuko Nakagawa; Ichiro Maeda; Manabu Kubota; Shigeko Ohnuma; Koichiro Tsugawa; Tomohiko Ohta; Marta Roche-Molina; Juan A Bernal; Ana J Narváez; Anand D Jeyasekharan; Ko Sato Journal: PLoS One Date: 2015-02-13 Impact factor: 3.240